文章名稱(chēng)引用次數(shù)

• MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment13
• The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know11
• Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease10
• Will CAR T cell therapy have a role in AML? Promises and pitfalls10
• Immune reconstitution after T-cell replete HLA-haploidentical transplantation9
• Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease9
• Complement in Pathophysiology and Treatment of Transplant -Associated Thrombotic Microangiopathies9
• Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods8
• Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study7
• Fetal Hemoglobin Induction by Epigenetic Drugs7